https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36396 Wed 28 Feb 2024 14:54:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34498 ref). Dosimetric endpoints were based on dose-volume histograms calculated from the CT_ref and the pCTs for various volumes of interest and on 3-dimensional gamma analyses. The PBM uncertainties were compared with those of the ABM and BDM. Results: The mean absolute error and mean error obtained from the PBM were 41.1 and –1.1 Hounsfield units. The PBM dose-volume histogram differences were 0.7% for prostate planning target volume V_95%, 0.5% for rectum V_70Gy, and 0.2% for bladder V_50Gy. Compared with ABM and BDM, PBM provided significantly lower dose uncertainties for the prostate planning target volume (70-78 Gy), the rectum (8.5-29 Gy, 40-48 Gy, and 61-73 Gy), and the bladder (12-78 Gy). The PBM mean gamma pass rate (99.5%) was significantly higher than that of ABM (94.9%) or BDM (96.1%). Conclusions: The proposed PBM provides low uncertainties with dose planned on CTref. These uncertainties were smaller than those of ABM and BDM and are unlikely to be clinically significant.]]> Wed 23 Feb 2022 16:03:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47143 Wed 14 Dec 2022 15:27:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32516 Wed 13 Jun 2018 11:02:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28108 Wed 10 Nov 2021 15:04:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53707 Wed 10 Jan 2024 11:03:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44516 95% of fractions were successfully delivered. The secondary outcomes were (1) the improvement in beam-target geometric alignment, (2) the improvement in dosimetric coverage of the prostate and avoidance of critical structures, and (3) no acute grade ≥3 genitourinary or gastrointestinal toxicity. Results: All 858 planned fractions were successfully delivered with MLC tracking, demonstrating the primary outcome of feasibility (P < .001). MLC tracking improved the beam-target geometric alignment from 1.4 to 0.90 mm (root-mean-square error). MLC tracking improved the dosimetric coverage of the prostate and reduced the daily variation in dose to critical structures. No acute grade ≥3 genitourinary or gastrointestinal toxicity was observed. Conclusions: Electromagnetic-guided MLC tracking radiation therapy for prostate cancer is feasible. The patients received improved geometric targeting and delivered dose distributions that were closer to those planned than they would have received without electromagnetic-guided MLC tracking. No significant acute toxicity was observed.]]> Wed 09 Nov 2022 10:02:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48759 10 pack years and/or distant metastases). Patients were randomized (1:1) to receive radiation therapy (70 Gy in 35 fractions) with either weekly cisplatin, 7 doses of 40 mg/m2, or cetuximab, loading dose of 400 mg/m2 followed by 7 weekly doses of 250 mg/m2. The primary outcome was symptom severity assessed by the MD Anderson Symptom Inventory Head and Neck Symptom Severity Scale from baseline to 13 weeks postcompletion of radiation therapy using the area under the curve. Trial was registered on ClinicalTrials.gov: NCT01855451. Results: Between June 17, 2013, and June 7, 2018, 189 patients were enrolled, with 92 in cisplatin arm and 90 in cetuximab included in the main analysis. There was no difference in the primary endpoint of symptom severity; difference in area under the curve cetuximab-cisplatin was 0.05 (95% confidence interval [CI], –0.19, 0.30), P = .66. The T-score (mean number of ≥grade 3 acute adverse events) was 4.35 (standard deviation 2.48) in the cisplatin arm and 3.82 (standard deviation 1.8) in the cetuximab arm, P = .108. The 3-year failure-free survival rates were 93% (95% CI, 86%-97%) in the cisplatin arm and 80% (95% CI, 70%-87%) in the cetuximab arm (hazard ratio = 3.0 [95% CI, 1.2-7.7]); P = .015. Conclusions: For patients with low-risk HPV-associated oropharyngeal cancer, radiation therapy and cetuximab had inferior failure-free survival without improvement in symptom burden or toxicity compared with radiation therapy and weekly cisplatin. Radiation therapy and cisplatin remain the standard of care.]]> Wed 05 Apr 2023 13:48:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55237 Wed 01 May 2024 15:42:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53466 Tue 28 Nov 2023 15:54:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49877 Thu 08 Jun 2023 15:49:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34316 Thu 03 Feb 2022 12:21:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32260 Thu 01 Jun 2023 10:46:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7789 Sat 24 Mar 2018 08:39:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7041 Sat 24 Mar 2018 08:37:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18126 Sat 24 Mar 2018 08:04:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21106 Sat 24 Mar 2018 07:53:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20181 Sat 24 Mar 2018 07:51:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20180 Sat 24 Mar 2018 07:51:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21552 p > 0.9) were found between CT and pseudo-CT Hounsfield units for organs of interest. Mean ± standard deviation DSC scores for the atlas-based segmentation of the pelvic bones were 0.79 ± 0.12, 0.70 ± 0.14 for the prostate, 0.64 ± 0.16 for the bladder, and 0.63 ± 0.16 for the rectum. Conclusions: The electron-density atlas method provides the ability to automatically define organs and map realistic electron densities to MRI scans for radiotherapy dose planning and DRR generation. This method provides the necessary tools for MRI-alone treatment planning and adaptive MRI-based prostate radiation therapy.]]> Sat 24 Mar 2018 07:50:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26356 Sat 24 Mar 2018 07:35:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23697 4 cm typically resulted in <1% of the heart volume receiving 5 Gy or less. It was more difficult to meet the heart dose constraint for left-sided and medially located tumors. Conclusions: Partial breast irradiation using 3-dimensional conformal RT was feasible within the study constraints. The ratio of planning target volume to ipsilateral whole-breast volume and the distance of surgical cavity from the heart were significant predictors of the quality of treatment plan for external beam PBI.]]> Sat 24 Mar 2018 07:13:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22668 Sat 24 Mar 2018 07:12:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46578 2-weighted MRIs were acquired in addition to planning CTs. The pCTs were generated from the MRIs using 7 configurations: 4 GANs (L2, single-scale PL, multiscale PL, weighted multiscale PL), 2 U-Net (L2 and single-scale PL), and the PBM. The imaging endpoints were mean absolute error and mean error, in Hounsfield units, between the reference CT (CT_ref) and the pCT. Dose uncertainties were quantified as mean absolute differences between the dose volume histograms (DVHs) calculated from the CT_ref and pCT obtained by each method. Three-dimensional gamma indexes were analyzed. Results: Considering the image uncertainties in the whole pelvis, GAN L2 and U-Net L2 showed the lowest mean absolute error (≤34.4 Hounsfield units). The mean errors were not different than 0 (P ≤ .05). The PBM provided the highest uncertainties. Very few DVH points differed when comparing GAN L2 or U-Net L2 DVHs and CT_ref DVHs (P ≤ .05). Their dose uncertainties were ≤0.6% for the prostate planning target Volume V_95%, ≤0.5% for the rectum V_70Gy, and ≤0.1% for the bladder V_50Gy. The PBM, U-Net PL, and GAN PL presented the highest systematic dose uncertainties. The gamma pass rates were >99% for all DLMs. The mean calculation time to generate 1 pCT was 15 s for the DLMs and 62 min for the PBM. Conclusions: Generating pCT for MRI dose planning with DLMs and PBM provided low-dose uncertainties. In particular, the GAN L2 and U-Net L2 provided the lowest dose uncertainties together with a low computation time]]> Mon 28 Nov 2022 16:01:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48895 Mon 01 May 2023 09:48:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45459 Fri 28 Oct 2022 14:22:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42286 Fri 17 Nov 2023 11:23:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32698 Fri 03 Dec 2021 10:35:45 AEDT ]]>